Drug intelligence / Profile preview

CoLig-10

Development stage: Unknown
Lead developer: Tetra Corporation
Modality: Small Molecules, Peptides, Recombinant Proteins and Enzymes
Administration: Oral

Overview

CoLig-10 is a multi-ingredient dietary supplement developed by Tetra Corporation to support joint health and nourish connective tissues. The formulation includes structural components such as collagen and hyaluronic acid, which are essential for the integrity of ligaments, tendons, and cartilage. It also incorporates a suite of antioxidants, including resveratrol, grape seed extract, green tea extract, and alpha-lipoic acid, along with specific vitamins and amino acids that facilitate collagen synthesis. CoLig-10 is indicated for the relief of joint pain, stiffness, swelling, and arch pain, and is typically distributed through healthcare providers.

Brand names: CoLig-10CoLig10CoLig 10

Beyond the preview

Go deeper on CoLig-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoLig-10.

Explore the full profile